Reprieve Cardiovascular

We’re thrilled to announce that Reprieve Cardiovascular has been nominated for the Emerging MedTech Company of the Year award at this year’s #NEVYs24, hosted by the New England Venture Capital Association! It is an honor to stand among this distinguished group of trailblazers in Healthcare, MedTech, Life Sciences, Tech, and Tough Tech, as part of the #NEVYsSurvivor event. Check out the full nominee list here: bit.ly/48yZ7pV Curious about how we’re transforming heart failure management? Visit our website to learn more: https://reprievecardio.com #NEVCA #Innovation

We are excited to announce the completion of enrollment in the "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)” trial. The FASTR trial aims to compare the effectiveness of decongestive therapy administered by the Reprieve System with Optimal Diuretic Therapy in patients diagnosed with acute decompensated heart failure. Completing enrollment in the FASTR trial marks a significant milestone for Reprieve as we advance our mission to improve the lives of patients living with heart failure. Go here to learn more: https://lnkd.in/ehrB84_U

Today, we highlighted findings from the TREAT-AHF study that were published in JACC: Heart Failure (https://bit.ly/4a4WqM5). The key finding: despite significant efforts to improve acute heart failure treatment over the past 20 years, management remains unchanged.   TREAT-AHF is a national community-based cohort study that characterizes a diverse population of 262,673 patients with HF from 2015 to 2022.   “Reprieve is committed to understanding the ADHF patient journey. The clinical evidence from the TREAT-HF study demonstrates that heart failure decongestion management has not substantially changed in 20 years. The data highlights the opportunities to improve care, but it will take a sustained partnership among hospital systems, physicians, nurses, and industry partners to solve this. Reprieve is committed to building these partnerships,” said Mark Pacyna, chief executive officer of Reprieve Cardiovascular. Reprieve is partnering with industry-leading heart failure researchers and Truveta to understand and advance acute heart failure patient outcomes. The partnership with Truveta contributed to the TREAT-AHF analysis and the publication of the manuscripts. Go here to learn more: https://bit.ly/44wkeYc

Today, we are thrilled to announce that Reprieve has secured a total of $42 million in series A financing.   The round, co-led by Lightstone Ventures and Sante Health Ventures II LP and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures, will enable us to accelerate the development of our clinical programs, including the ongoing FASTR trial and upcoming pivotal trial.   Heart failure affects millions worldwide, with over 1 million patients in the U.S. alone admitted annually due to primary heart failure diagnoses. At Reprieve, our mission is to pioneer intelligent fluid management solutions for acute decompensated heart failure (ADHF) patients, ultimately improving outcomes and reducing hospital readmissions.   The Reprieve System has the potential to monitor physiological parameters such as urine output to deliver personalized diuretic dosing and fluid replacement for patients with ADHF, while also providing physicians with real-time insights to optimize patient care. By empowering care teams with enhanced visibility and control, we aim to transform the standard of care for heart failure patients worldwide.   Go here to learn more: https://bit.ly/3uGRkae